{
    "id": 16273,
    "fullName": "EGFR dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "EGFR dec exp indicates decreased expression of the Egfr protein. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "dec exp",
    "createDate": "01/08/2016",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3866,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS-mutant lung adenocarcinoma with low EGFR expression in culture and improved overall survival in low EGFR expressing, KRAS-mutant lung adenocarcinoma cell line xenograft models, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16550,
                "profileName": "EGFR dec exp KRAS mut"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3865,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant non-small cell lung cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16550,
                "profileName": "EGFR dec exp KRAS mut"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3867,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16550,
                "profileName": "EGFR dec exp KRAS mut"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8042,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model with low expression of wild-type EGFR, that also harbors a KRAS mutation (PMID: 27040853).",
            "molecularProfile": {
                "id": 16550,
                "profileName": "EGFR dec exp KRAS mut"
            },
            "therapy": {
                "id": 4625,
                "therapyName": "Cisplatin + ER2",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5133,
                    "pubMedId": 27040853,
                    "title": "ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27040853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3871,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16552,
                "profileName": "EGFR dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3873,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of GA201 and Camptosar (irinotecan) resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to either as a single agent (PMID: 23209031).",
            "molecularProfile": {
                "id": 16552,
                "profileName": "EGFR dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 3373,
                "therapyName": "GA201 + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5546,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung carcinoma cell lines demonstrating lower basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) were resistant to Pan-HER in culture (PMID: 26420857).",
            "molecularProfile": {
                "id": 20977,
                "profileName": "EGFR dec exp ERBB2 dec exp ERBB3 dec exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5547,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines demonstrating lower basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) were resistant to Pan-HER in culture (PMID: 26420857).",
            "molecularProfile": {
                "id": 20977,
                "profileName": "EGFR dec exp ERBB2 dec exp ERBB3 dec exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased expression of Egfr and Rictor using siRNA resulted in increased sensitivity to Oncovin (vincristine) in glioblastoma cell lines in culture, including both PTEN wild-type and PTEN mutant cell lines (PMID: 23555046).",
            "molecularProfile": {
                "id": 29889,
                "profileName": "EGFR dec exp RICTOR dec exp"
            },
            "therapy": {
                "id": 1631,
                "therapyName": "Vincristine",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4768,
                    "pubMedId": 23555046,
                    "title": "Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23555046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased expression of Egfr and Rictor using siRNA resulted in increased sensitivity to Temodar (temozolomide) in glioblastoma cell lines in culture, including both PTEN wild-type and PTEN mutant cell lines (PMID: 23555046).",
            "molecularProfile": {
                "id": 29889,
                "profileName": "EGFR dec exp RICTOR dec exp"
            },
            "therapy": {
                "id": 1141,
                "therapyName": "Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4768,
                    "pubMedId": 23555046,
                    "title": "Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23555046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16549,
            "profileName": "EGFR dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16550,
            "profileName": "EGFR dec exp KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16552,
            "profileName": "EGFR dec exp KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19446,
            "profileName": "EGFR dec exp PTEN mut RICTOR dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19447,
            "profileName": "EGFR dec exp PTEN wild-type RICTOR dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20977,
            "profileName": "EGFR dec exp ERBB2 dec exp ERBB3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29889,
            "profileName": "EGFR dec exp RICTOR dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}